Ocella
Product Images NDC 53002-1577

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ocella (NDC 53002-1577). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2 (7ae51f8c 8ea0 4502 8d7b D0c0b1a295ba 02)

FDA Label Image

Structural Formulas (7ae51f8c 8ea0 4502 8d7b D0c0b1a295ba 03)

Drospirenone and Ethinyl estradiol are two active ingredients commonly found in combination birth control pills. Drospirenone is a synthetic form of progesterone, while Ethinyl estradiol is a synthetic form of estrogen. Together, they work to prevent pregnancy by inhibiting ovulation, thickening cervical mucus, and altering the lining of the uterus. These ingredients are effective and commonly prescribed by healthcare providers for contraception purposes.*

FDA Label Image

Pregnancy Diagram (7ae51f8c 8ea0 4502 8d7b D0c0b1a295ba 04)

This text appears to be discussing different methods of birth control. It mentions various options such as implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, spermicide, withdrawal, and not having sex during the most fertile days of the monthly cycle. The text also includes statistics on the number of pregnancies per 100 women, ranging from fewer than 1 to 85 or more.*

FDA Label Image

Ocella Foil (7ae51f8c 8ea0 4502 8d7b D0c0b1a295ba 05)

FDA Label Image

Blood Clot Diagram (7ae51f8c 8ea0 4502 8d7b D0c0b1a295ba 06)

The text provides information about various ranges and factors related to pregnancy, postpartum, and the risk of blood clots. It mentions different categories such as non-pregnant, non-COC users, COC users, pregnancy, and postpartum. It also includes the number of women with a blood clot out of 10,000 Women Years. Additionally, it notes that the pregnancy data is based on the actual duration of pregnancy in reference studies and provides the rate of blood clot risk assuming a nine-month pregnancy duration.*

FDA Label Image

Fig 1 (Image 01)

FDA Label Image

Figure 3: Relative Studies Of Risk Of Breast Cancer With Combined Oral Contraceptives (Image 02)

FDA Label Image

Label Image (Lbl530021577)

Not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.